Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
Kailera Therapeutics appointed Kathleen Tregoning as Chief Corporate Affairs Officer, leveraging her experience from Cerevel, Sanofi, and Biogen to support its obesity care pipeline. Ms. Tregoning currently serves as an independent director on the board of Compass Pathways (Nasdaq: CMPS) and Spero Therapeutics (Nasdaq: SPRO), maintaining her governance roles while joining Kailera.
Key figures
- Drug Name
- ribupatide injection (KAI-9531)
- Phase Of Trial
- Phase 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.